Phase i trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma

Melanoma Research

Volumn 24, Issue 4, 2014, Pages 342-348

  Alrwas, Anas ^a   Papadopoulos, Nicholas E ^b   Cain, Suzanne ^b   Patel, Sapna P ^b   Kim, Kevin B ^b   Deburr, Tawania L ^b   Bassett, Roland ^b   Hwu, Wen Jen ^b   Bedikian, Agop Y ^b   Davies, Michael A ^b   Woodman, Scott E ^b   Hwu, Patrick ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biochemotherapy; brain metastasis; melanoma; nab paclitaxel; temozolomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; B RAF KINASE INHIBITOR; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; LACTATE DEHYDROGENASE; MELAN A; PACLITAXEL; PROTEIN S 100; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CHILL; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; FATIGUE; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MAXIMUM TOLERATED DOSE; METASTATIC MELANOMA; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; SIDE EFFECT; SURVIVAL RATE; TASTE; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; MELANOMA; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84904034885     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000062     Document Type: Article

References (24)

1. Legha S, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon-alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759.
2. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garwski E, et al. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs 1991; 9:59-64.
3. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of Taxol in metastatic melanoma. Cancer 1990; 65:2478-2481.
4. Walker L, Schalch H, King DM, Dietich L, Eastman M, Kwak M, et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res 2005; 15:453-459.
5. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 2004; 14:63-66.
6. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, et al. Phase I/II study of a cisplatin-Taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol 2009; 32:509-514.
7. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12:1317-1324.
8. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803.
9. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997; 108:210-214.
10. Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010; 116:155-163.
11. Kottschade LA, Suman VJ, Amatruda T III, McWilliams RR, Mattar BI, Nikcevich DA, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer 2011; 117:1704-1710.
12. Gonzá lez Cao M, Malvehy J, Martí R, Conill C, Sanchez M, Martin M, et al. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma Res 2006; 16:59-64.
13. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
14. Sherring-Plough Corp. Data on file. Study C193-114. Kenilworth, NJ: Sherring-Plough Corp; 1998.
15. National Cancer Institute. CTEP: NCI Guidance on CTC Terminology Applications. Bethesda, MD: National Cancer Institute; 2006.
16. Stinchcombe TE, Socinski MA,Walko CM, O'Neil BH, Collichio FA, Ivanova MJ, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007; 60: 759-766.
17. Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 2001; 7:2611-2619.
18. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748-5754.
19. Bedikian AY, Johnson MM,Warneke CL, Mcintyre S, Papadopoulos N, HwuWJ, et al. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 2008; 5:201-207.
20. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921-2929.
21. Ron IG, Sarid D, Rvvo L, Sapir EE, Schneebaum S, Mester U, et al. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma Res 2006; 16: 65-69.
22. Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Piqozzo J, et al. Central nervous system failure in melanoma patients: results of a randomized, multicentre phase 3 study of temozolomide-and dacarbazinebased regimens. Br J Cancer 2011; 104:1816-1821.
23. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11-20.
24. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 2011; 34:603-610.